Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | GABBR2 | O75899 | 4/20 | 0.36 |
| ▸ | GABBR1 | Q9UBS5 | 4/20 | 0.36 |
| ▸ | CPA1 | P15085 | 3/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6479633 | 0.83 | CNR1 (0.38) | CNR1ALOX5ALDH1A1LMNACYP3A4 | |
| SCHEMBL2040186 | 0.81 | KDM4E (0.42) | CNR1ALOX5ALDH1A1LMNACYP1A2 | |
| SCHEMBL22831452 | 0.79 | GABBR2 (0.58) | GABBR2GABBR1CPA1ALDH1A1LMNA | |
| SCHEMBL29147714 | 0.79 | GABBR2 (0.58) | GABBR2GABBR1CPA1ALDH1A1LMNA | |
| SCHEMBL21686411 | 0.75 | GABBR2 (0.61) | CNR1GABBR2GABBR1ALDH1A1LMNA | |
| SCHEMBL21686319 | 0.75 | SERPINH1 (0.43) | CNR1GABBR2GABBR1ALDH1A1LMNA | |
| SCHEMBL9988481 | 0.75 | GABBR2 (0.61) | CNR1GABBR2GABBR1ALDH1A1LMNA | |
| SCHEMBL27725190 | 0.75 | GABBR2 (0.61) | CNR1GABBR2GABBR1ALDH1A1LMNA | |
| SCHEMBL28158048 | 0.75 | GABBR2 (0.38) | GABBR2GABBR1ALOX5LMNACYP1A2 | |
| SCHEMBL9324364 | 0.72 | CNR1 (0.45) | CNR1ALOX5ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034093-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20240358675-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-10-31 | — | — | US | disclosed |
| CN-118165002-A | Polycyclic compounds and methods of use thereof | 桑诺维恩药品公司 | 2024-06-11 | — | — | CN | disclosed |
| EP-3252057-B1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2024-03-27 | — | — | EP | disclosed |
| US-20220387382-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220387382-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-10894033-B2 | Multicyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-10894033-B2 | Multicyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-20200323819-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2020-10-15 | — | — | US | disclosed |
| US-20200323819-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2020-10-15 | — | — | US | disclosed |
| US-8710245-B2 | Multicyclic compounds and methods of use thereof | PSYCHOGENICS INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710245-B2 | Multicyclic compounds and methods of use thereof | PSYCHOGENICS INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710245-B2 | Multicyclic compounds and methods of use thereof | PSYCHOGENICS INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130109677-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PSYCHOGENICS INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130109677-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PSYCHOGENICS INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130109677-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PSYCHOGENICS INC. (US) | 2013-05-02 | — | — | US | disclosed |
| CN-102762575-A | Polycyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC | 2012-10-31 | — | — | CN | disclosed |
| EP-2507245-A2 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2012-10-10 | — | — | EP | disclosed |
| WO-2011069063-A2 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011069063-A2 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387382-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | CNR1 137/4885GABBR2 52/4885GABBR1 33/4885 |
| US-20200323819-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | CNR1 137/4885GABBR2 52/4885GABBR1 33/4885 |
| US-20240358675-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | CNR1 137/4885GABBR2 52/4885GABBR1 33/4885 |
| US-10894033-B2 | Multicyclic compounds and methods of use thereof | GRIN2C, NLN, COMT | CNR1 137/4885GABBR2 52/4885GABBR1 33/4885 |
| US-20130109677-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | CNR1 137/4885GABBR2 52/4885GABBR1 33/4885 |
| US-20260034093-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SLC6A3, SLC6A11, SLC6A13 | CNR1 130/4885GABBR2 583/4885GABBR1 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.